Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Study of MPDL3280A + SAR in Stage IV NSCLC
NCT02400814Phase 1Terminated
- Start
- Dec 2015
- Primary completion
- Sep 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of atezolizumab in non-small cell lung cancer (NSCLC) (3 arms). Primary endpoints: Incidence of adverse events and Objective Response Rate. Started Dec 2015; status: terminated.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02400814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02400814.